Cytovation AS   Report issue

For profit Phase 2
Founded: Bergen Norway (2014)

Organization Overview

First Clinical Trial
2020
NCT04260529
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Cytovation AS

Active Ingredients

Drugs in Phase 2 Trials (2)

cypep-1 (2 trials)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2